About Chai Discovery
Chai Discovery is an AI-driven drug discovery company that develops frontier models and computational tools to predict and reprogram interactions between molecules. The company's mission is to transform biology from a scientific practice into an engineering discipline, enabling rational drug design where therapeutic candidates can be generated computationally and ready for IND-enabling studies. Their flagship technology, Chai-2, represents a breakthrough in de novo antibody design, capable of designing full-length, drug-like monoclonal antibodies (mAbs) with atomic precision. The platform achieves double-digit success rates for antibodies and over 50% success rates for miniproteins, allowing researchers to bypass traditional high-throughput screening. Chai-2 can target challenging proteins including GPCRs and membrane proteins, design for specific epitopes, handle post-translational modifications, and control for species specificity. The company has established major partnerships with leading pharmaceutical companies including Eli Lilly and Pfizer. Chai Discovery's technology addresses traditionally "hard to drug" targets and has demonstrated sub-angstrom level structural accuracy validated through cryo-EM studies. The company serves pharmaceutical companies, biotechnology firms, and academic researchers working on biologics discovery and therapeutic development.
Mission & Story
Mission
Transform biology from a scientific practice into an engineering discipline
Founding Story
Founded by a team from OpenAI, the company emerged from OpenAI's offices to become one of the flashiest names in AI drug development
Clinical Focus
Medical conditions and clinical areas addressed by Chai Discovery.
Who It Serves
Milestones & Awards
Recent Milestones
$130M Series B at $1.3B valuation (Dec 2025), collaboration with Eli Lilly (Jan 2026), license agreement with Pfizer (Jun 2026), partnership with Lilly TuneLab (Jun 2026), Chai-2 antibody design capabilities announced (Nov 2025)
Awards & Recognition
Became AI unicorn at $1.3B valuation, backed by OpenAI
Key Partnerships
Company Details
- Founded
- 2024
- Headquarters
- San Francisco, CA, USA
- Employees
- 25-100
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.